Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial

Trial Profile

Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Padeliporfin (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2018 Status changed from recruiting to discontinued due to concerns about post VTP MRI results being conclusive
    • 10 Aug 2015 Accrual to date is 62 % according to United Kingdom Clinical Research Network.
    • 08 Aug 2015 Accrual to date is 50% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top